PUBLISHER: TechNavio | PRODUCT CODE: 1915582
PUBLISHER: TechNavio | PRODUCT CODE: 1915582
Global Immunotherapy Drugs Market 2025-2029
The global immunotherapy drugs market is forecasted to grow by USD 220790.9 mn during 2024-2029, accelerating at a CAGR of 12.4% during the forecast period. The report on the global immunotherapy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating incidence of chronic diseases and cancer, pioneering technological and therapeutic innovations, robust investment and strategic collaborations in research and development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2029 |
| Series Year | 2025-2029 |
| Growth Momentum | Accelerate |
| YOY 2025 | 11.3% |
| CAGR | 12.4% |
| Incremental Value | $220790.9 mn |
Technavio's global immunotherapy drugs market is segmented as below:
By End-User
- Hospitals
- Clinics
- Others
By Type
- Monoclonal antibodies
- Vaccines
- Immune checkpoint inhibitors
- Others
By Therapeutic Area
- Cancer
- Autoimmune and inflammatory diseases
- Infectious diseases
- Others
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the ascendancy of personalized cancer vaccines as one of the prime reasons driving the global immunotherapy drugs market growth during the next few years. Also, expansion and innovation in car-t cell therapy and rapid development and approval of bispecific antibodies will lead to sizable demand in the market.
The report on the global immunotherapy drugs market covers the following areas:
- Global immunotherapy drugs market sizing
- Global immunotherapy drugs market forecast
- Global immunotherapy drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global immunotherapy drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, BioNTech SE, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc, F. Hoffmann La Roche Ltd., Genmab AS, Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Johnson and Johnson Services, Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Ltd.. Also, the global immunotherapy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Therapeutic Area
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
5 Historic Market Size
- 5.1 Global Immunotherapy Drugs Market 2019 - 2023
- Historic Market Size - Data Table on Global Immunotherapy Drugs Market 2019 - 2023 ($ million)
- 5.2 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ million)
- 5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ million)
- 5.4 Therapeutic Area segment analysis 2019 - 2023
- Historic Market Size - Therapeutic Area Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI in global immunotherapy drugs market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
8 Market Segmentation by End-user
- 8.1 Market segments
- 8.2 Comparison by End-user
- 8.3 Hospitals - Market size and forecast 2024-2029
- 8.4 Clinics - Market size and forecast 2024-2029
- 8.5 Others - Market size and forecast 2024-2029
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
9 Market Segmentation by Type
- 9.1 Market segments
- 9.2 Comparison by Type
- 9.3 Monoclonal antibodies - Market size and forecast 2024-2029
- 9.4 Vaccines - Market size and forecast 2024-2029
- 9.5 Immune checkpoint inhibitors - Market size and forecast 2024-2029
- 9.6 Others - Market size and forecast 2024-2029
- 9.7 Market opportunity by Type
- Market opportunity by Type ($ million)
10 Market Segmentation by Therapeutic Area
- 10.1 Market segments
- 10.2 Comparison by Therapeutic Area
- 10.3 Cancer - Market size and forecast 2024-2029
- 10.4 Autoimmune and inflammatory diseases - Market size and forecast 2024-2029
- 10.5 Infectious diseases - Market size and forecast 2024-2029
- 10.6 Others - Market size and forecast 2024-2029
- 10.7 Market opportunity by Therapeutic Area
- Market opportunity by Therapeutic Area ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- 12.3.1 US - Market size and forecast 2024-2029
- 12.3.2 Canada - Market size and forecast 2024-2029
- 12.3.3 Mexico - Market size and forecast 2024-2029
- 12.4 Europe - Market size and forecast 2024-2029
- 12.4.1 Germany - Market size and forecast 2024-2029
- 12.4.2 UK - Market size and forecast 2024-2029
- 12.4.3 France - Market size and forecast 2024-2029
- 12.4.4 Italy - Market size and forecast 2024-2029
- 12.4.5 Russia - Market size and forecast 2024-2029
- 12.4.6 Spain - Market size and forecast 2024-2029
- 12.4.7 The Netherlands - Market size and forecast 2024-2029
- 12.5 Asia - Market size and forecast 2024-2029
- 12.5.1 China - Market size and forecast 2024-2029
- 12.5.2 Japan - Market size and forecast 2024-2029
- 12.5.3 India - Market size and forecast 2024-2029
- 12.5.4 South Korea - Market size and forecast 2024-2029
- 12.5.5 Singapore - Market size and forecast 2024-2029
- 12.5.6 Indonesia - Market size and forecast 2024-2029
- 12.5.7 Thailand - Market size and forecast 2024-2029
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- 12.6.1 Brazil - Market size and forecast 2024-2029
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- 12.6.3 South Africa - Market size and forecast 2024-2029
- 12.6.4 Turkey - Market size and forecast 2024-2029
- 12.6.5 UAE - Market size and forecast 2024-2029
- 12.6.6 Australia - Market size and forecast 2024-2029
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Escalating incidence of chronic diseases and cancer
- Pioneering technological and therapeutic innovations
- Robust investment and strategic collaborations in research and development
- 13.2 Market challenges
- High cost of treatment and reimbursement hurdles
- Mechanisms of therapeutic resistance and management of toxicities
- Complex manufacturing processes and supply chain logistics
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Ascendancy of personalized cancer vaccines
- Expansion and innovation in CAR-T cell therapy
- Rapid development and approval of bispecific antibodies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 15.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.8 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 15.9 Boehringer Ingelheim GmbH
- Boehringer Ingelheim GmbH - Overview
- Boehringer Ingelheim GmbH - Product / Service
- Boehringer Ingelheim GmbH - Key news
- Boehringer Ingelheim GmbH - Key offerings
- SWOT
- 15.10 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.11 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.12 Genmab AS
- Genmab AS - Overview
- Genmab AS - Product / Service
- Genmab AS - Key offerings
- SWOT
- 15.13 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- SWOT
- 15.14 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.15 Johnson and Johnson Services
- Johnson and Johnson Services - Overview
- Johnson and Johnson Services - Business segments
- Johnson and Johnson Services - Key news
- Johnson and Johnson Services - Key offerings
- Johnson and Johnson Services - Segment focus
- SWOT
- 15.16 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.17 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 15.18 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
